Lung Cancer
A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)
- Details
ClinicalTrials.gov ID:
NCT06767514
Diagnosis Type:
NA
USOR Number:
- Address
,
P: